Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BridgeBio Pharma (BBIO) Debt Ratio (2019 - 2025)

Historic Debt Ratio for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to 0.74.

  • BridgeBio Pharma's Debt Ratio rose 1306.17% to 0.74 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.74, marking a year-over-year increase of 1306.17%. This contributed to the annual value of 0.8 for FY2024, which is 163.95% down from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Debt Ratio is 0.74, which was up 1306.17% from 0.8 recorded in Q4 2024.
  • BridgeBio Pharma's Debt Ratio's 5-year high stood at 0.87 during Q2 2023, with a 5-year trough of 0.09 in Q1 2021.
  • For the 5-year period, BridgeBio Pharma's Debt Ratio averaged around 0.55, with its median value being 0.58 (2022).
  • As far as peak fluctuations go, BridgeBio Pharma's Debt Ratio skyrocketed by 51825.46% in 2022, and later crashed by 3732.33% in 2024.
  • Over the past 5 years, BridgeBio Pharma's Debt Ratio (Quarter) stood at 0.43 in 2021, then surged by 62.65% to 0.69 in 2022, then rose by 18.12% to 0.82 in 2023, then decreased by 1.64% to 0.8 in 2024, then dropped by 7.72% to 0.74 in 2025.
  • Its Debt Ratio was 0.74 in Q3 2025, compared to 0.8 in Q4 2024 and 0.66 in Q3 2024.